Open-Label, Single Arm, Phase 3b, Multi-Center Study Evaluating the Impact of Venetoclax on the Quality of Life of Relapsed/Refractory Subjects with Chronic Lymphocytic Leukemia (CLL) Including Those with the 17p Deletion or TP53 Mutation OR Those Who Have Received Prior Treatment with a B-Cell Receptor Inhibitor
Phase of Trial: Phase III
Latest Information Update: 03 Nov 2017
At a glance
- Drugs Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors AbbVie
- 30 Oct 2017 Planned End Date changed from 17 Jan 2023 to 15 Nov 2022.
- 02 Aug 2017 Planned End Date changed from 4 Dec 2022 to 17 Jan 2023.
- 10 Jun 2017 Biomarkers information updated